financetom
Business
financetom
/
Business
/
Lennar Reports Mixed Q2 Results: EPS Miss, Revenues Beat
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lennar Reports Mixed Q2 Results: EPS Miss, Revenues Beat
Jun 16, 2025 3:50 PM

Lennar Corp. ( LEN ) released its second-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter. 

The Details: Lennar reported quarterly earnings of $1.90 per share, which missed the Street estimate of $1.94. Quarterly revenue of $8.38 billion beat the analyst consensus estimate of $8.16 billion.

Read Next: These Are The 3 Hottest Stock Market Themes Trending Now

For the second quarter, Lennar ( LEN ) reported:

New orders increased 6% to 22,601 homes.

Backlog of 15,538 homes with a dollar value of $6.5 billion.

Deliveries increased 2% to 20,131 homes.

Homebuilding operating earnings of $728 million

Gross margin on home sales of 17.8%.

SG&A expenses as a percentage of revenues from home sales of 8.8%.

Net margin on home sales of 8.9%.

Financial Services operating earnings of $157 million.

“While we continue to see softness in the housing market due to affordability challenges and a decline in consumer confidence, we adhered to our strategy of driving starts, sales, and closings in order to build long-term efficiencies in our business,” Stuart Miller, Co-CEO of Lennar ( LEN ), said.

LEN Price Action: According to data from Benzinga Pro, Lennar ( LEN ) stock was up 2.58% at $112.32 in Monday's extended trading. 

Read Next: 

‘Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,’ Says ‘Black Swan’ Author Nassim Taleb 

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mastercard Partners With Alipay for Global Fund Transfers to China
Mastercard Partners With Alipay for Global Fund Transfers to China
Mar 19, 2024
09:36 AM EDT, 03/19/2024 (MT Newswires) -- Mastercard ( MA ) said Tuesday it has partnered with Alipay for global fund transfers to China. Financial terms weren't disclosed. Alipay is a Chinese digital open platform under Ant Group, the company added. Price: 479.93, Change: +1.03, Percent Change: +0.22 ...
Fastenal Insider Sold Shares Worth $832,453, According to a Recent SEC Filing
Fastenal Insider Sold Shares Worth $832,453, According to a Recent SEC Filing
Mar 19, 2024
09:37 AM EDT, 03/19/2024 (MT Newswires) -- Charles S. Miller, SENIOR EXECUTIVE VP, on March 15, 2024, sold 11,076 shares in Fastenal ( FAST ) for $832,453. Following the Form 4 filing with the SEC, Miller has control over a total of 13,151 shares of the company, with 13,151 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/815556/000141588924008305/xslF345X03/form4-03182024_090342.xml Price: 75.43, Change: -0.27, Percent...
Siemens's share slump to one-year low after CFO's gloomy outlook
Siemens's share slump to one-year low after CFO's gloomy outlook
Mar 19, 2024
(Reuters) - Shares in Siemens slumped to their lowest in one year after its finance chief Ralf Thomas commented that revenues at its flagship digital industries division will be flat in the second quarter at a Bank of America ( BAC ) conference on Tuesday. Thomas said the German technology conglomerate forecasts revenue at the division to be a good...
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why
Mar 19, 2024
Tuesday, Seelos Therapeutics Inc ( SEEL ) provided an update on top-line data of the Phase 2/3 HEALEY ALS Platform trial.  The study was designed to evaluate SLS-005 (IV trehalose), a low molecular weight disaccharide that stabilizes misfolded proteins and activates autophagy, in decreasing the slope of the ALS Functional Rating Scale (ALSFRS-R) and separation from placebo in Function and Mortality in an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved